Blue Trust’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-18
Closed -$392 – 2637
2026
Q1
$392 Hold
18
– – ﹤0.01% 2366
2025
Q4
$387 Hold
18
– – ﹤0.01% 2427
2025
Q3
$347 Sell
18
-3,264
-99% -$58.2K ﹤0.01% 2465
2025
Q2
$56.1K Buy
3,282
+2,771
+542% +$118K ﹤0.01% 1400
2025
Q1
$32.6K Buy
511
+30
+6% +$3.16K ﹤0.01% 1532
2024
Q4
$58.5K Sell
481
-87
-15% -$10.7K ﹤0.01% 1188
2024
Q3
$89.7K Buy
568
+511
+896% +$70.6K ﹤0.01% 1277
2024
Q2
$7.38K Buy
57
+48
+533% +$6.17K ﹤0.01% 2046
2024
Q1
$1.16K Sell
9
-58
-87% -$7.1K ﹤0.01% 1914
2023
Q4
$8K Buy
+67
New +$6.43K ﹤0.01% 1680
2023
Q1
– Sell
-10
Closed -$1K – 2615
2022
Q4
$1K Hold
10
– – ﹤0.01% 2137
2022
Q3
$1K Buy
10
+7
+233% +$706 ﹤0.01% 2007
2022
Q2
$0 Buy
+3
New +$221 ﹤0.01% 2004

Other funds holding SRPT

Blue Trust's SRPT Position: Q2 2026 in Review

Blue Trust sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 18 shares — an estimated $392 sold.

Blue Trust first reported a position in SRPT in Q2 2022 and held it in 13 quarters. The position peaked at $89.7K in Q3 2024. 326 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Blue Trust reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blue Trust sold 18 Sarepta Therapeutics shares in Q2 2026, an estimated $392.
  • Blue Trust first reported a position in Sarepta Therapeutics in Q2 2022 and held it in 13 quarters.
  • Blue Trust's Sarepta Therapeutics position peaked at $89.7K in Q3 2024.
  • 326 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Blue Trust's 13F filing for Q2 2026, filed 21 Jul 2026.